Results 31 to 40 of about 25,581,606 (307)

Prognostic significance of folate metabolism polymorphisms for lung cancer. [PDF]

open access: yes, 2007
Functional nonsynonymous single-nucleotide polymorphisms (nsSNPs) of folate metabolism genes can influence the methylation of tumour suppressor genes, thereby potentially impacting on tumour behaviour.
El Galta, R   +13 more
core   +1 more source

Immunotherapy of lung cancer: An update [PDF]

open access: yes, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Hatz, R. A.   +15 more
core   +1 more source

Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer [PDF]

open access: yes, 2010
Lung cancer is the leading cause of cancer deaths, because ~84% of cases are diagnosed at an advanced stage. Worldwide in 2008, ~1.5 million people were diagnosed and ~1.3 million died – a survival rate unchanged since 1960.
Alex Stewart   +68 more
core   +1 more source

CD133 and non-small-cell lung cancer [PDF]

open access: yesEuropean Journal of Cardio-Thoracic Surgery, 2010
The striking prevalence in women is well documented since many years, with about 80—90% clearly resulting from the smaller dimensions of the airways in women (see also the comment by Sameh Sensar in ICVTS 3(2004) 404). Thus, there is no consensus about the treatment modalities, but there is an explicit trend to conservative treatment since one of the ...
openaire   +2 more sources

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

Quality of life in patients receiving platinum based chemotherapy for advanced non-small cell lung cancer. [PDF]

open access: yes, 2006
Quality of life in patients receiving platinum based chemotherapy for advanced non-small cell lung cancer. Lung cancer is the cause of 34,000 deaths in the UK each year, with a five year survival rate of only 7.5%.
Leary, A.
core  

Chemotherapy in non-small cell lung cancer

open access: yesAnnals of Oncology, 1995
Non-small cell lung cancer can no longer be regarded as resistant to chemotherapy, and there have recently been considerable improvements in the use of the older agents and advances in the identification of new drugs. Recent meta-analysis has also confirmed the view that chemotherapy can have small but modest survival benefits.
N, Thatcher   +4 more
openaire   +2 more sources

The heterodimeric amino acid transporters (HAT) of the SLC7/SLC3 family: A structure−function relationships and relevance to human pathology

open access: yesFEBS Letters, EarlyView.
Heterodimeric amino acid transporters consist of SLC7 and SLC3 family proteins arranged in a conserved structural organization. They regulate nutrient transport across cell membranes, supporting essential cellular functions. These transporters also contribute to xenobiotic/drug uptake and distribution.
Mariafrancesca Scalise   +5 more
wiley   +1 more source

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

open access: yesFEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos   +9 more
wiley   +1 more source

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

open access: yesDrugs in Context, 2022
Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common KRAS ...
Biagio Ricciuti   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy